A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, and Clinical Efficacy of Seltorexant (JNJ-42847922) on Behavioral and Psychological Symptoms of Dementia in Patients With Probable Alzheimer's Disease
Latest Information Update: 27 Nov 2024
At a glance
- Drugs Seltorexant (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
Most Recent Events
- 27 Mar 2024 Status changed from recruiting to completed.
- 11 May 2023 Planned primary completion date changed from 19 Apr 2023 to 16 Oct 2023.
- 30 Mar 2023 Planned End Date changed from 17 Aug 2023 to 16 Oct 2023.